<DOC>
	<DOCNO>NCT00932373</DOCNO>
	<brief_summary>This phase I , multicenter , open-label , dose-escalation study single-agent trastuzumab-MCC-DM1 administer intravenous ( IV ) infusion patient HER2-positive metastatic breast cancer ( MBC ) previously receive trastuzumab . The study ass safety , tolerability , pharmacokinetics trastuzumab-MCC-DM1 determine dose schedule use Phase II .</brief_summary>
	<brief_title>A Study Trastuzumab-MCC-DM1 Administered Intravenously Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received Trastuzumab-Containing Regimen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Histologically document , incurable , locally advanced metastatic breast cancer Evaluable measurable HER2positive disease History progression within 60 day treatment prior trastuzumabcontaining chemotherapy regimen HER2positive breast cancer Previous treatment chemotherapy MBC Granulocyte count ≥ 1,500/μL , platelet count ≥ 100,000/μL , hemoglobin ≥ 9 g/dL Serum bilirubin ≤ 1.5 mg/dL ; AST , ALT , alkaline phosphatase ≤ 2.5 × upper limit normal ( ULN ) except : Patients hepatic metastasis : ALT AST ≤ 5 × ULN Patients hepatic and/or bone metastasis : alkaline phosphatase ≤ 5 × ULN Serum creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 60 mL/min base 24hour urine collection Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 Women childbearing potential men must agree use effective method birth control ( e.g. , hormonal , barrier ) receiving study treatment History significant cardiac disease , unstable angina , CHF , myocardial infarction , ventricular arrhythmia require medication History Grade ≥ 3 hypersensitivity reaction trastuzumab History toxicity trastuzumab result trastuzumab permanently discontinue Symptomatic brain metastasis radiation surgery brain metastasis within 3 month first study treatment Require supplemental oxygen daily activity Grade ≥ 2 peripheral neuropathy Bisphosphonate therapy symptomatic hypercalcemia Any chemotherapy , hormonal therapy , radiotherapy , immunotherapy , biologic therapy treatment breast cancer within 4 week first study treatment Any experimental therapy within 4 week first study treatment Any major surgical procedure within 4 week first study treatment History clinically symptomatic liver disease , include viral hepatitis , current history alcoholism , cirrhosis Pregnancy lactation Cardiac troponin I ≥ 0.2 ng/mL Ejection fraction &lt; 50 % low limit normal determine echocardiogram MUGA scan Prior cumulative doxorubicin dose &gt; 360 mg/m2 equivalent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>MBC</keyword>
	<keyword>Trastuzumab emtansine</keyword>
	<keyword>Herceptin</keyword>
	<keyword>T-DM1</keyword>
</DOC>